JP2016530291A - 脆弱ｘ症候群および関連障害の処置方法 - Google Patents

脆弱ｘ症候群および関連障害の処置方法 Download PDF

Info

Publication number
JP2016530291A
JP2016530291A JP2016539645A JP2016539645A JP2016530291A JP 2016530291 A JP2016530291 A JP 2016530291A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016530291 A JP2016530291 A JP 2016530291A
Authority
JP
Japan
Prior art keywords
metadoxine
mice
treatment
administration
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016539645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530291A5 (enExample
Inventor
ヤーロン、ダニエリ
ダリア、メギド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcturus Therapeutics Ltd
Original Assignee
Alcobra Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed by Alcobra Ltd filed Critical Alcobra Ltd
Publication of JP2016530291A publication Critical patent/JP2016530291A/ja
Publication of JP2016530291A5 publication Critical patent/JP2016530291A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
JP2016539645A 2013-09-09 2014-09-09 脆弱ｘ症候群および関連障害の処置方法 Pending JP2016530291A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US14/038,258 2013-09-26
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Publications (2)

Publication Number Publication Date
JP2016530291A true JP2016530291A (ja) 2016-09-29
JP2016530291A5 JP2016530291A5 (enExample) 2017-10-19

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016539645A Pending JP2016530291A (ja) 2013-09-09 2014-09-09 脆弱ｘ症候群および関連障害の処置方法
JP2016540930A Pending JP2016530536A (ja) 2013-09-09 2014-09-09 療法に対する奏効性の決定方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016540930A Pending JP2016530536A (ja) 2013-09-09 2014-09-09 療法に対する奏効性の決定方法

Country Status (12)

Country Link
EP (2) EP3043792A2 (enExample)
JP (2) JP2016530291A (enExample)
KR (2) KR20160086818A (enExample)
CN (2) CN105917225A (enExample)
AU (2) AU2014315026A1 (enExample)
CA (2) CA2923421A1 (enExample)
EA (2) EA201690559A1 (enExample)
IL (2) IL244343A0 (enExample)
MX (2) MX2016003002A (enExample)
SG (2) SG11201601830PA (enExample)
TW (2) TW201605443A (enExample)
WO (2) WO2015033224A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521274A (ja) * 2020-02-07 2023-05-24 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109021022B (zh) * 2013-07-31 2021-04-16 Udc 爱尔兰有限责任公司 发光的二氮杂苯并咪唑碳烯金属配合物
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
WO2019197632A1 (en) * 2018-04-13 2019-10-17 Healx Limited Treatment of fragile x syndrome
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
PL3813816T3 (pl) * 2018-06-07 2023-07-31 Ovid Therapeutics Inc. Zastosowanie kwasu (s)-3-amino-4-(difluorometylenylo)cyklopentano-1-eno-1-karboksylowego i związków pokrewnych, kwasu (1s,3s)-3-amino-4-(difluorometylideno)cyklopentano-1-karboksylowego w leczeniu zespołu łamliwego chromosomu x lub zespołu drżenia/ataksji związanego z zespołem łamliwego chromosomu x
CN115335053B (zh) * 2020-01-08 2024-08-09 株式会社纽若梵提 包含麦角乙脲化合物作为有效成分用于治疗脆性x染色体综合征或相关发育障碍的组合物
EP4171528A1 (en) * 2020-06-29 2023-05-03 Zynerba Pharmaceuticals, Inc. Treatment of fragile x syndrome with cannabidiol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
JP2012531402A (ja) * 2009-06-25 2012-12-10 アルコブラ、リミテッド 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
JP2012531402A (ja) * 2009-06-25 2012-12-10 アルコブラ、リミテッド 認知疾患、障害または病態の治療、症状緩和、軽減、改善および予防方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521274A (ja) * 2020-02-07 2023-05-24 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物
JP7412583B2 (ja) 2020-02-07 2024-01-12 ニューロヴェンティ カンパニー リミテッド リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物

Also Published As

Publication number Publication date
WO2015033224A2 (en) 2015-03-12
EA201690557A1 (ru) 2016-07-29
KR20160086818A (ko) 2016-07-20
CN105917225A (zh) 2016-08-31
TW201606304A (zh) 2016-02-16
SG11201601605YA (en) 2016-04-28
EA201690559A1 (ru) 2016-08-31
EP3044589A1 (en) 2016-07-20
IL244453A0 (en) 2016-04-21
KR20160078956A (ko) 2016-07-05
CN105517546A (zh) 2016-04-20
AU2014315026A1 (en) 2016-03-24
WO2015035402A1 (en) 2015-03-12
CA2923421A1 (en) 2015-03-12
MX2016003006A (es) 2016-06-10
JP2016530536A (ja) 2016-09-29
WO2015033224A3 (en) 2015-07-02
MX2016003002A (es) 2016-09-08
IL244343A0 (en) 2016-04-21
CA2922901A1 (en) 2015-03-12
EP3043792A2 (en) 2016-07-20
TW201605443A (zh) 2016-02-16
AU2014316779A1 (en) 2016-03-17
SG11201601830PA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
JP2016530291A (ja) 脆弱ｘ症候群および関連障害の処置方法
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
CA2580619C (en) Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
JP2010504338A (ja) 筋萎縮性側索硬化症（ＡＬＳ）の治療のための水素化ピリド［４，３−ｂ］インドール
JP2021521122A (ja) 筋萎縮性側索硬化症および関連障害の治療のための併用療法
WO2001068136A1 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
JP2012528818A (ja) Ｃｍｔ及び関連障害を処置するための新たな組成物
AU2016268096B2 (en) Extended release pharmaceutical compositions of levetiracetam
JP2019527216A (ja) ジアミノフェノチアジンの投与及び投与量
JP7296472B2 (ja) プリドピジンを使用したミトコンドリア関連疾患および障害（それらの症状を含む）の治療
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN109069450A (zh) 神经障碍的新的组合疗法
WO2020165802A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
US9851354B2 (en) Methods of treating fragile X syndrome and related disorders
JP2023546924A (ja) 神経系障害を処置するための抗プリン作動性組成物の投与
US20110065674A1 (en) Methods and compositions for improving cognitive function
AU2018309710A1 (en) Methods and compositions for treating neurological conditions
AU2011235981B2 (en) Use of Memantine (Namenda) to Treat Autism, Compulsivity, and Impulsivity
JPWO2001068136A1 (ja) 糖尿病性合併症及び神経障害用の薬剤とその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204